Abstract
The author discusses barriers to psychopahrmacological research, including attacks by vocal human rights groups, regulation by local review boards, and Department of Health, Education, and Welfare restrictions. He suggests that those patients least able to give informed consent are most in need of the benefits of research on new drugs.

This publication has 0 references indexed in Scilit: